Metastatic breast cancer (MBC) is defined as breast cancer that has spread beyond the breast and nearby lymph nodes to distant organs, marking the disease as stage 4.
How genetics influence risk and progression
Two broad categories of genetic changes affect susceptibility to breast cancer that can later become metastatic. Germline mutations exist in every cell and are inherited from a parent. About 5–10% of breast cancer cases arise from such hereditary predisposition, with BRCA1 and BRCA2 being the most frequently cited examples.
Somatic mutations develop after birth, arising in a single cell and its descendants. These changes are not passed down to offspring. Both germline and somatic alterations can contribute to tumors that progress to MBC, though the mechanisms differ.
Testing and its role in treatment decisions
Diagnosing MBC follows the same pathway as earlier stages—laboratory analysis, imaging, and biopsies. Genetic testing is not used to confirm the presence of metastasis, but it can be ordered after a diagnosis to guide therapy.
Related: Strength training lowers women’s heart attack risk 44%
When a tumor carries a germline BRCA mutation, clinicians may prescribe poly(ADP‑ribose) polymerase (PARP) inhibitors, a class of drugs that target cells with defective DNA repair. For somatic mutations such as those in the PIK3CA gene, the drug alpelisib offers a targeted option. An ESR1 mutation may make a patient eligible for the selective estrogen receptor degrader elacestrant.
Testing can also reveal trial eligibility.
Beyond drug selection, test results can open doors to clinical trials, granting access to emerging therapies that are not yet part of standard practice.
Who should consider genetic testing?
Guidelines suggest testing for individuals who have a close blood relative with a known pathogenic variant, those with a personal history of breast cancer meeting specific age or diagnostic criteria, or anyone whose family history aligns with these risk factors. The information gleaned can be valuable not only for the patient but also for relatives who may share the same genetic risk.
Related: 5 things to consider before stopping BP meds
Standard treatment regimens for MBC remain centered on systemic therapies—chemotherapy, immunotherapy, hormone therapy, and targeted agents—often combined to improve outcomes. Radiation or surgery may be employed for palliation, though such approaches are less common.
Understanding the genetics of metastatic disease helps clinicians move from a one‑size‑fits‑all approach toward more personalized care, which can be especially important when conventional options have limited effectiveness.
Risk factors beyond genetics
While hereditary mutations are a clear risk factor, other tumor characteristics also influence the likelihood of metastasis. For instance, cancers that are HER2‑positive tend to spread more readily to the liver, lungs, and brain. Nonetheless, not every HER2‑positive case will become metastatic, and many patients with other subtypes also develop advanced disease.
Early detection and effective initial treatment continue to be the primary means of preventing progression, highlighting the importance of routine screening and prompt medical attention when symptoms arise.
Leave a Reply